Harry J. Leonhardt
2017 - Halozyme Therapeutics
In 2017, Harry J. Leonhardt earned a total compensation of $1.8M as Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary at Halozyme Therapeutics, a 10% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $242,582 |
|---|---|
| Option Awards | $550,000 |
| Salary | $425,000 |
| Stock Awards | $550,006 |
| Other | $11,070 |
| Total | $1,778,658 |
Leonhardt received $550K in stock awards, accounting for 31% of the total pay in 2017.
Leonhardt also received $242.6K in non-equity incentive plan, $550K in option awards, $425K in salary and $11.1K in other compensation.
Rankings
In 2017, Harry J. Leonhardt's compensation ranked 6,091st out of 14,666 executives tracked by ExecPay. In other words, Leonhardt earned more than 58.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,091 out of 14,666 | 59th |
Division Manufacturing | 2,241 out of 5,772 | 61st |
Major group Chemicals And Allied Products | 709 out of 2,075 | 66th |
Industry group Drugs | 546 out of 1,731 | 69th |
Industry Biological Products, Except Diagnostic Substances | 100 out of 313 | 68th |
Source: SEC filing on March 22, 2018.
Leonhardt's colleagues
We found four more compensation records of executives who worked with Harry J. Leonhardt at Halozyme Therapeutics in 2017.
News
Poseida Therapeutics CEO Mark Gergen's 2022 pay jumps 55% to $4.4M
April 26, 2023
Poseida Therapeutics CEO Eric Ostertag's 2021 pay jumps 633% to $6.3M
April 27, 2022
Halozyme Therapeutics CEO Helen Torley's 2019 pay rises 1% to $5.9M
March 20, 2020
Halozyme Therapeutics CEO Helen Torley's 2018 pay rises 12% to $5.8M
March 22, 2019